Joakim Bedner Stenbäck

Mr. Joakim Bedner Stenbäck

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 March 2025
Verified
Preprint
Open access
PDF file
JSJoakim Bedner Stenbäck
Joakim Bedner Stenbäck
JRJohan Ringlander
Johan Ringlander
This protocol outlines the steps for preparing and sequencing the hepatitis B virus (HBV) whole genome using Oxford Nanopore MinION with Flongle flowcells. It details primer-based amplification, quality control using Agilent TapeStation, and library preparation using the Oxford Nanopore RBK114.24 or RBK114.96 barcoding sequencing kit.

15 September 2026 in Viruses
Verified
Journal Article
Open access
PDF file
KLKatarina Lund
Katarina Lund
MFMiriam Frankal
Miriam Frankal
AEAnders Eilard
Anders Eilard
JSJoakim Bedner Stenbäck
Joakim Bedner Stenbäck
EAErik Alestig
Erik Alestig
MLMagnus Lindh
Magnus Lindh
Hepatitis B surface antigen (HBsAg) loss is rarely achieved during long-term nucleos(t)ide analogue (NUC) therapy of chronic hepatitis B. Treatment discontinuation may lead to immune activation and HBsAg loss. In a prospective study, HBeAg-negative patients without liver cirrhosis stopped NUC therapy after a duration of at least 3 years. Follow-up for 2 years comprised monthly monitoring for the first six months. Twenty-five patients who discontinued therapy and six randomized controls who continued were included. After stopping NUC therapy, five patients (20%) developed an HBsAg seroclearance pattern, including four who lost HBsAg and one who achieved HBsAg below 1 IU/mL. Seven patients (28%) developed a state of immune control with persistently low HBV DNA and normal ALT. Six patients (24%) experienced severe flares requiring NUC re-initiation; all of them, including one with fulminant hepatitis necessitating liver transplantation, had detectable hepatitis B core-related antigen (HBcrAg) in serum at NUC discontinuation. The peak serum HBV DNA level strongly correlated with and preceded peak ALT. Thus, although half of the patients had favorable outcomes, there was a substantial risk of severe flares preceded by HBV DNA levels above 6 log10 IU/mL. Close monitoring, including frequent HBV DNA testing with rapid turnaround time, is therefore essential.

8 December 2025
Verified
Preprint
Open access
JSJoakim Bedner Stenbäck
Joakim Bedner Stenbäck
JRJohan Ringlander
Johan Ringlander
This protocol outlines the steps for preparing and sequencing the hepatitis B virus (HBV) whole genome using Oxford Nanopore MinION with Flongle flowcells. It details primer-based amplification, quality control using Agilent TapeStation, and library preparation using the Oxford Nanopore RBK114.24 or RBK114.96 barcoding sequencing kit.

2 September 2026 in Journal of Medical Virology
Verified
Journal Article
Open access
MFMichael Xiangchen Fu
Michael Xiangchen Fu
Maria PerdomoMaria Perdomo
Maria Perdomo
SLSheila F. Lumley
Sheila F. Lumley
JRJohan Ringlander
Johan Ringlander
KKKai Kean
Kai Kean
HHHeli Harvala
Heli Harvala
This multicentre study investigated the utility of next‐generation sequencing (NGS) to detect and generate hepatitis B virus (HBV) genomes in samples of low viral load (from 0.2 to 6207 IU/mL). 23 HBV DNA‐positive plasma samples of genotypes A‐E and one HBV‐negative control sample were assayed blindly via 9 established NGS methods from 6 European laboratories. Methods included untargeted metagenomics, pre‐enrichment by probe‐capture followed by Illumina sequencing, and HBV‐specific PCR pre‐amplification followed by sequencing with Nanopore or Illumina. Full HBV genomes were obtained only from samples with viral loads > 1000 IU/mL using probe‐capture methods, > 200 IU/mL using PCR‐Illumina methods, > 10 IU/mL using PCR‐Nanopore methods, and in no samples using metagenomic methods. Contamination was observed in the negative control and samples with very low viral loads in PCR‐based methods. Probe‐capture and metagenomic methods detected additional viruses not routinely screened in blood donations, including polyomaviruses and herpesviruses; positive results were confirmed by PCR. In conclusion, NGS may delineate whole‐genome sequences at low viral loads if supported by a PCR pre‐amplification step. Probe‐capture methods also reliably detect HBV without pre‐amplification but show limited genome coverage for samples with low viral loads; they may additionally detect a wide range of blood‐borne viruses.